Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Consolidation Chemotherapy/mortality"'
Autor:
Stephan Fuhrmann, Peter Brossart, Markus Munder, Mathias Hänel, Anja Seckinger, Katja Weisel, Hartmut Goldschmidt, Helga Bernhard, Jan Dürig, Anna Jauch, Martin Goerner, Christina Kunz, Hans-Walter Lindemann, Steffen Luntz, Ahmet H. Elmaagacli, Igor Wolfgang Blau, Hans Salwender, Maximilian Merz, Sandra Sauer, Marc S. Raab, Martin Hoffmann, Elias K. Mai, Kaya Miah, Axel Benner, Dirk Hose, Uta Bertsch, Christof Scheid
Publikováno v:
Leukemia
Intensive upfront therapy in newly-diagnosed multiple myeloma (MM) including induction therapy (IT), high-dose melphalan (MEL200), and autologous blood stem cell transplantation (ASCT) followed by consolidation and/or maintenance is mostly restricted
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abdfae6314551f474fd5c284e7f37463
https://doi.org/10.1038/s41375-020-0976-9
https://doi.org/10.1038/s41375-020-0976-9
Autor:
Martin Goerner, Markus Munder, Martin Hoffmann, Katja Weisel, Peter Brossart, Elias K. Mai, Anja Seckinger, Hans Salwender, Bernhard Rabold, Dirk Hose, Thomas Hielscher, Igor Wolfgang Blau, Uta Bertsch, Steffen Luntz, Ahmet H. Elmaagacli, Stefanie Huhn, Nicola Giesen, Hartmut Goldschmidt, Jens Hillengass, Marc S. Raab, Christina Kunz, Christof Scheid, Anna Jauch, Maximilian Merz, Diana Tichy, Barbara Hügle-Dörr, Hans-Walter Lindemann, Mathias Hänel, Helga Bernhard, Jan Dürig, Stephan Fuhrmann
Publikováno v:
Leukemia. 34:1853-1865
The MM5 trial aimed at demonstrating a progression-free survival (PFS) difference in continued vs. response-adapted (in case of complete response, CR) lenalidomide (LEN) maintenance therapy (MT) in newly diagnosed, transplant-eligible multiple myelom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37d3744d392b8b60be666bc6b8b4d70d
https://doi.org/10.1038/s41375-020-0724-1
https://doi.org/10.1038/s41375-020-0724-1